Nephros (NEPH) Competitors $4.08 +0.10 (+2.51%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NEPH vs. CVRX, LNSR, AVR, PDEX, RCEL, INFU, LUCD, LAKE, PTHL, and OBIOShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include CVRx (CVRX), LENSAR (LNSR), Anteris Technologies Global (AVR), Pro-Dex (PDEX), Avita Medical (RCEL), InfuSystem (INFU), Lucid Diagnostics (LUCD), Lakeland Industries (LAKE), Pheton (PTHL), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Nephros vs. Its Competitors CVRx LENSAR Anteris Technologies Global Pro-Dex Avita Medical InfuSystem Lucid Diagnostics Lakeland Industries Pheton Orchestra BioMed Nephros (NASDAQ:NEPH) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings. Do institutionals and insiders have more ownership in NEPH or CVRX? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 6.7% of Nephros shares are owned by insiders. Comparatively, 13.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is NEPH or CVRX more profitable? Nephros has a net margin of 5.16% compared to CVRx's net margin of -97.49%. Nephros' return on equity of 9.43% beat CVRx's return on equity.Company Net Margins Return on Equity Return on Assets Nephros5.16% 9.43% 7.20% CVRx -97.49%-79.04%-42.37% Does the media favor NEPH or CVRX? In the previous week, CVRx had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for CVRx and 1 mentions for Nephros. CVRx's average media sentiment score of 0.80 beat Nephros' score of 0.00 indicating that CVRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, NEPH or CVRX? Nephros has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Which has stronger earnings & valuation, NEPH or CVRX? Nephros has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$14.16M3.05$70K$0.0758.29CVRx$51.29M3.34-$59.97M-$2.18-3.02 Do analysts recommend NEPH or CVRX? Nephros presently has a consensus target price of $5.00, indicating a potential upside of 22.55%. CVRx has a consensus target price of $14.50, indicating a potential upside of 120.36%. Given CVRx's higher probable upside, analysts clearly believe CVRx is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CVRx 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryCVRx beats Nephros on 9 of the 16 factors compared between the two stocks. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.72M$10.52B$5.53B$9.04BDividend YieldN/A2.07%5.24%4.01%P/E Ratio58.2917.0327.6420.25Price / Sales3.0529.53416.59118.23Price / Cash201.3922.9936.8958.07Price / Book5.043.668.035.67Net Income$70K$235.40M$3.18B$249.21M7 Day Performance5.70%2.15%2.92%3.28%1 Month Performance20.00%3.38%3.72%5.55%1 Year Performance96.15%-10.18%35.14%21.08% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros0.8695 of 5 stars$4.08+2.5%$5.00+22.5%+96.6%$42.72M$14.16M58.2930News CoveragePositive NewsCVRXCVRx2.7486 of 5 stars$5.88+1.0%$14.50+146.6%-44.0%$151.74M$51.29M-2.70160Positive NewsLNSRLENSAR1.4068 of 5 stars$13.17+3.2%$15.00+13.9%+189.2%$150.47M$53.49M-2.72110News CoverageAVRAnteris Technologies GlobalN/A$3.79-6.7%$16.50+335.4%N/A$146.41M$2.70M0.00138News CoveragePositive NewsPDEXPro-Dex2.4928 of 5 stars$43.64-2.8%$56.00+28.3%+178.5%$146.36M$53.84M15.59140Positive NewsHigh Trading VolumeRCELAvita Medical0.8784 of 5 stars$5.29-2.9%$16.50+211.9%-29.2%$144.07M$64.25M-2.42130INFUInfuSystem1.9381 of 5 stars$6.24+2.0%$13.00+108.3%N/A$131.14M$137.58M104.02410High Trading VolumeLUCDLucid Diagnostics2.3657 of 5 stars$1.15-1.7%$3.55+208.7%+44.5%$126.58M$4.35M-0.8670LAKELakeland Industries4.8318 of 5 stars$13.61+3.3%$26.00+91.0%-39.2%$125.40M$167.21M-4.522,100High Trading VolumePTHLPhetonN/A$18.39+0.8%N/AN/A$120.06M$450K0.0011High Trading VolumeOBIOOrchestra BioMed2.8167 of 5 stars$2.68-3.6%$14.20+429.9%-61.8%$106.51M$2.64M-1.514High Trading Volume Related Companies and Tools Related Companies CVRx Competitors LENSAR Competitors Anteris Technologies Global Competitors Pro-Dex Competitors Avita Medical Competitors InfuSystem Competitors Lucid Diagnostics Competitors Lakeland Industries Competitors Pheton Competitors Orchestra BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEPH) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEPH Stock Alerts